Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on December 14, 2020, covering events occurring on December 14 and December 17, 2020. The filing details changes to the composition of the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation.
Material Changes
- Appointment of Director: The Board appointed Dr. Mary Ann Gray as a Class II director effective December 17, 2020. Her term expires at the 2022 annual meeting.
- Committee Assignments: Dr. Gray was appointed Chair of the Audit Committee and a member of the Compensation Committee.
- Resignation of Director: Dr. Alon Lazarus resigned from the Board and its Audit and Compensation Committees effective December 17, 2020. The resignation was not due to any disagreement with the Company.
- Updated Committee Membership:
- Audit Committee: Mary Ann Gray (Chair), Nima Farzan, Carl Gordon.
- Compensation Committee: Ran Nussbaum (Chair), Nima Farzan, Mary Ann Gray.
- Nominating and Corporate Governance Committee: Tomer Kariv (Chair), Julius Knowles.
Guidance, Outlook, and Compensation Details
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. It details the following compensatory arrangements for Dr. Gray:
- Initial Stock Option: Granted 16,587 shares at the closing price on December 17, 2020, vesting in equal quarterly installments over three years.
- Annual Stock Option: Eligible for an annual grant of 8,293 shares in connection with future Annual Meetings.
- Cash Retainers: $35,000 annual retainer for Board service, plus $15,000 for Audit Committee Chair and $5,000 for Compensation Committee membership.
- Indemnification: The Company will enter into a standard indemnification agreement covering expenses, damages, and legal fees incurred in her capacity as a director.
Investor Verification Checklist
- Verify the effective date of Dr. Lazarus's resignation and Dr. Gray's appointment (December 17, 2020).
- Confirm the specific share counts and vesting schedules for Dr. Gray's initial and annual stock option grants.
- Review the attached press release (Exhibit 99.1) for additional context on the Board's rationale for these changes.
- Check subsequent filings to confirm the updated Board composition remains in effect.